A phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC79037) in the palliative management of advanced gastrointestinal cancer.
D000368:Aged; D000740:Anemia / Q000139:chemically induced; D001791:Blood Platelet Disorders / Q000139:chemically induced; D003510:Cyclohexanes / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009603:Nitroso Compounds / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010166:Palliative Care; D013997:Time Factors; D014508:Urea / Q000627:therapeutic use*
D003510:Cyclohexanes; D009603:Nitroso Compounds; D009607:Nitrosourea Compounds; D014508:Urea